Interpreting patient-reported outcomes from clinical trials in COPD: a discussion

References

• Global Initiative for Chronic Obstructive Lung Disease [homepage on the Internet]Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease2016 www.goldcopd.orgAccessed July 16, 2016
   Google Scholar
• National Institute for Health and Care Excellence [webpage on the Internet]Chronic Obstructive Pulmonary Disease Pathway2015 http://pathways.nice.org.uk/pathways/chronic-obstructive-pulmonary-diseaseAccessed August 24, 2015
   Google Scholar
• RennardSThomashowBCrapoJIntroducing the COPD foundation guide for diagnosis and management of COPD, recommendations of the COPD foundationCOPD J Chronic Obstr Pulm Dis2013103378389
   Web of Science ®Google Scholar
• European Medicines AgencyReflection Paper on the Regulatory Guidance for the Use of Health-Related Quality of Life (HRQL) Measures in the Evaluation of Medicinal ProductsLondonEuropean Medicines Agency2005
   Google Scholar
• US Department of Health and Human ServicesChronic Obstructive Pulmonary Disease: Developing Drugs for Treatment – Guidance for IndustrySilver Spring, MD2016 http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm071575.pdfAccessed July 16, 2016
   Google Scholar
• SchulzKFAltmanDGMoherDCONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trialsBMJ2010340c33220332509
   PubMed Web of Science ®Google Scholar
• JonesPWBeehKMChapmanKRDecramerMMahlerDAWedzichaJAMinimal clinically important differences in pharmacological trialsAm J Respir Crit Care Med2014189325025524383418
   PubMed Web of Science ®Google Scholar
• RennardSIMinimal clinically important difference, clinical perspective: an opinionCOPD200521515517136962
   PubMedGoogle Scholar
• NormanGRSloanJAWyrwichKWInterpretation of changes in health-related quality of life: the remarkable universality of half a standard deviationMed Care200341558259212719681
   PubMed Web of Science ®Google Scholar
• JonesPWSt George’s Respiratory Questionnaire: MCIDCOPD200521757917136966
   PubMedGoogle Scholar
• KarnerCChongJPoolePTiotropium versus placebo for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20147CD009285
   Google Scholar
• CopeSDonohueJFJansenJPComparative efficacy of long-acting bronchodilators for COPD: a network meta-analysisRespir Res20131410024093477
   PubMed Web of Science ®Google Scholar
• DonohueJFMaleki-YazdiMRKilbrideSMehtaRKalbergCChurchAEfficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPDRespir Med2013107101538154623830094
   PubMed Web of Science ®Google Scholar
• JonesPWQuirkFHBaveystockCMLittlejohnsPA self-complete measure of health status for chronic airflow limitation. The St George’s Respiratory QuestionnaireAm Rev Respir Dis19921456132113271595997
   PubMed Web of Science ®Google Scholar
• JonesPWBoshTKQuality of life changes in COPD patients treated with salmeterolAm J Respir Crit Care Med19971554128312899105068
   PubMed Web of Science ®Google Scholar
• WellingJBHartmanJETen HackenNHKloosterKSlebosD-JThe minimal important difference for the St George’s Respiratory Questionnaire in patients with severe COPDEur Respir J20154661598160426493797
   PubMed Web of Science ®Google Scholar
• AgustiACalverleyPMCelliBEvaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) InvestigatorsCharacterisation of COPD heterogeneity in the ECLIPSE cohortRespir Res20101112220831787
   PubMed Web of Science ®Google Scholar
• NormanGRSridharFGGuyattGHWalterSDRelation of distribution- and anchor-based approaches in interpretation of changes in health-related quality of lifeMed Care200139101039104711567167
   PubMed Web of Science ®Google Scholar
• JonesPWInterpreting thresholds for a clinically significant change in health status in asthma and COPDEur Respir J200219339840411936514
   PubMed Web of Science ®Google Scholar
• JonesPWGelhornHWilsonHResponder analyses for treatment effects in COPD using the SGRQ appear to be largely independent of the value used to determine a clinically significant responseAm J Respir Crit Care Med2015191A4454
   Web of Science ®Google Scholar
• JonesPWLeidyNKHareendranALamarcaRChuecosFGarcia GilEThe effect of aclidinium bromide on daily respiratory symptoms of COPD, measured using the evaluating respiratory symptoms in COPD (E-RS: COPD) diary: pooled analysis of two 6-month Phase III studiesRespir Res2016176127215749
   PubMed Web of Science ®Google Scholar
• BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J20134261484149423722616
   PubMed Web of Science ®Google Scholar
• BeehK-MBeierJDonohueJFClinical trial design in chronic obstructive pulmonary disease: current perspectives and considerations with regard to blinding of tiotropiumRespir Res2012135222726538
   PubMed Web of Science ®Google Scholar
• CalverleyPMAndersonJACelliBSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med2007356877578917314337
   PubMed Web of Science ®Google Scholar
• TashkinDPCelliBSennSA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med2008359151543155418836213
   PubMed Web of Science ®Google Scholar
• VogelmeierCHedererBGlaabTTiotropium versus salmeterol for the prevention of exacerbations of COPDN Engl J Med2011364121093110321428765
   PubMed Web of Science ®Google Scholar
• CasaburiRKukafkaDCooperCBWitekTJKestenSImprovement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPDChest2005127380981715764761
   PubMed Web of Science ®Google Scholar
• LavioletteLBourbeauJBernardSAssessing the impact of pulmonary rehabilitation on functional status in COPDThorax200863211512117901158
   PubMed Web of Science ®Google Scholar
• LandsbergerHAHawthorne RevisitedIthaca, NYThe New York State School of Industrial and Labor Relations1958
   Google Scholar
• McCarneyRWarnerJIliffeSvan HaselenRGriffinMFisherPThe Hawthorne effect: a randomised, controlled trialBMC Med Res Methodol2007713017608932
   PubMed Web of Science ®Google Scholar
• BarnettAGvan der PolsJCDobsonAJRegression to the mean: what it is and how to deal with itInt J Epidemiol200534121522015333621
   PubMed Web of Science ®Google Scholar
• JonesPWGelhornHWilsonHEffect of bronchodilator and placebo therapy on SGRQ score in patients over 3 years: difference between low/medium and high socio-economic countriesAm J Respir Crit Care Med2014189Meeting AbstractsA5962
   Google Scholar
• JonesPWHardingGBerryPWiklundIChenW-HKline LeidyNDevelopment and first validation of the COPD Assessment TestEur Respir J200934364865419720809
   PubMed Web of Science ®Google Scholar
• SinghDWorsleySZhuC-QHardakerLChurchAUmeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trialBMC Pulm Med2015159126286141
   PubMed Web of Science ®Google Scholar
• JonesPWResponsiveness of the COPD Assessment Test: the minimal clinically important difference does matter (response)Chest2012142126726822796862
   PubMed Web of Science ®Google Scholar
• KonSSCanavanJLJonesSEMinimum clinically important difference for the COPD Assessment Test: a prospective analysisLancet Respir Med20142319520324621681
   PubMed Web of Science ®Google Scholar